Earlier this week BioSante Pharma (BPAX) reported 3Q08 results which included a net loss of $6.6M or ($0.24) per share and a loss of $16.3M or ($0.60) per share for the first nine months of the year. The primary focus at the company is the development of LibiGel, which is currently being evaluated for both effectiveness and safety in three Phase 3 clinical trials for the treatment of female sexual dysfunction [FSD]. The Company ended 3Q08 with $17.5M in cash, compared to $2.8M at the end of 2Q08.
As illustrated on t










